VCEL Vericel Corproation

$-0.01 (-0.07%)

VCEL Stock Analysis Overview

What this means: Vericel Corproation (VCEL) gets an Overall Rank of 66, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. VCEL's 66 means that it ranks higher than 66% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full VCEL report

Vericel Corproation (VCEL) Analyst Forecast

Next 12 months ➝Current Price$14.2552-week High$19.9552-week Low$6.78MEAN$23.40+64.21%HIGH$32.00+124.56%LOW$20.00+40.35%
  • Last Price$14.25
  • Previous Close$14.26
  • Change $-0.01
  • Open$14.69
  • Volume253,261
  • Avg. Volume (100-day)750,827
  • Market Capitalization$643M
  • Days Range $14.15 - $14.69
  • 52-week Range $6.78 - $19.95
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-0.26
  • Earnings Date08/04/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta1.069
  • PEG Ratio
  • Volatility0.61
  • Average True Range0.08
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products and the goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs. The Company operates in one reportable segment: the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.